Actual Medicinal Product (AMP) Propafenone 150mg tablets (Alliance Healthcare (Distribution) Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Protect from light and store in airtight containers.
- Provenance
-
This compatibility recommendation is derived from Arythmol 150mg and 300mg tablets (Viatris UK Healthcare Ltd).
- Generic
- Propafenone
- Formulation
- Propafenone 150mg tablets
-
Propafenone
-
Propafenone 150mg tablets
-
Propafenone 150mg tablets (Alliance Healthcare (Distribution) Ltd)
-
-